Genmab A/S ADS (GMAB) is a publicly traded Healthcare sector company. As of May 21, 2026, GMAB trades at $26.90 with a market cap of $16.19B and a P/E ratio of 0.00. GMAB moved +6.00% today. Year to date, GMAB is -14.43%; over the trailing twelve months it is +33.84%. Its 52-week range spans $17.24 to $35.43. Analyst consensus is strong buy with an average price target of $36.69. Rallies surfaces GMAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Genmab slides after Q1 2026 report shows higher costs despite 25% revenue growth: Genmab reported Q1 2026 results today (May 7, 2026), with revenue up 25% year over year to $896 million while operating profit edged down to $180 million. The report maintained full-year 2026 guidance, but higher operating expenses and acquisition/integration charges weighed on sentiment.
| Metric | Value |
|---|---|
| Price | $26.90 |
| Market Cap | $16.19B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.43 |
| 52-Week Low | $17.24 |
| Volume | 10.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
9 analysts cover GMAB: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.69.